Premature Ejaculation Treatment Market - Global Industry Growth and Trend Analysis 2024-2032

Premature Ejaculation Treatment Market Synopsis:

Premature Ejaculation Treatment Market Size Was Valued at USD 2.45 Billion in 2023, and is Projected to Reach USD 5.20 Billion by 2032, Growing at a CAGR of 8.74% From 2024-2032.

The Premature Ejaculation Treatment Market includes all products and therapies geared for the treatment of PE – this is a condition under which a man ejaculates earlier than desired during intercourse, thus causing personal distress or reduced sexual pleasure. This market comprises medicines such as the drugs used to treat the condition, topical products, behavioural therapy, devices, and any other product that might assist an individual with the condition.

Regular ejaculation is a current and severe sexual dysfunction affecting men across the world, with immense health and social implications for their lives. The enhancement of knowledge and control of sexual health problems, alongside the rising need for minimally invasive treatment are anticipated to fuel the premature ejaculation treatment market. Lifestyle changes that are worse global health, elevated stress levels, and communion of alcohol/tobacco have been blamed due to early ejaculation. That way, there is increased market for male health and wellness and problem addressing hence more men are seeking medical help and treatment linked to sexual health.

The market is huge and consists of everything from SSRLs and local anesthetics to essential oils and over the counter topical creams. Also, non-drug therapies such as behaviour therapy, sexual techniques, and medical devices have gotten popular in the market. Increasing popularity of mental health therapies including the CBT applications is also emerging as chief driver to the market for premature ejaculation solutions. This sector is further benefiting from a rising trend where more men are coming forward for treatment early enough.

Premature Ejaculation Treatment Market Trend Analysis:

Increasing Adoption of Non-Pharmacological Treatments

• The use of non-drug methods of treating PE is another feature which can be seen in the market of premature ejaculation treatments. Currently, both patients and other service providers are shifting their attention on services that do not entail drugs. Therapies that are more topical and in particular behavioural therapies like, the “stop-start” technique as well as the use of desensitizing sprays or topical anesthetics are becoming very popular because they work and don’t seem to have very many side effects.
• Also, cognitive behavioural therapy (CBT) is gradually attaining recognition as being viable for addressing psychological causes of early discharge and provides patients with integrative management solutions. This shift is consistent with the current global outlook towards the sexual health, where persons are shifting from a normal pharmaceutical remedy and more into an organic approach.

Growing Market Potential in Emerging Economies

• The largest opportunities for market growth for premature ejaculation treatment lie in the emerging economies the awareness of the problems of sexual health is growing. They come in the form of aspirations for better healthcare, clean environment, weight loss, depression treatment, and sexual health in countries like India, China and Brazil, respectively. As the economic * conditions change and the health care structures develop in the countries, more men will require solutions to treat premature ejaculation making it a great opportunity.
• In addition, factors such as the availability of inexpensive drugs available over the counter and doctor’s prescription via electronic form will fuel growth in those markets. Consequently, EE serve as rich prospects for market development and niche saturation.

Premature Ejaculation Treatment Market Segment Analysis:

Premature Ejaculation Treatment Market Segmented on the basis of Treatment Type, Drug Type, and Region

By Treatment Type, Pharmaceutical Treatment segment is expected to dominate the market during the forecast period

• The Premature Ejaculation Treatment Market in terms of treatment can be classified into two broad categories namely pharmacological and non-pharmacological treatment. Medical therapies consist of drugs such as, SSRI’s, topical anaesthetics and PDE5 inhibitors which serves good purposes in terms of sexual function and delaying ejaculation. Such drugs are widely prescribed by patients who need immediate pain and inflammation reduction are sold in different forms like tablets, ointment, and aerosols.
• In contrast, non-pharmacologic therapies of PE include; the use of behavioural techniques, devices, non-prescribed means, and other interventions that try to tackle the actual cause of the problem. The two techniques include the stop-start approach and cognitive behavioural therapy that may be used to manage ejaculation. Some of the options include vibrator penile which has been used in the treatment of problems that may be associated with ejaculate control, other common treatments may include change of certain behaviour and counselling. They are becoming popular since patients are looking for other or additional ways to treating their ailments apart from taking medication.

By Drug Type, SSRIs (Selective Serotonin Reuptake Inhibitors) segment expected to held the largest share

• Preeminent classifications of the Premature Ejaculation Treatment Market based on the type of drugs are SSRIs, topical anesthetics, and PDE5 inhibitors. The primary category of drugs used for premature ejaculation is SSRIs, mainly due to the fact they prolong the sexual activity by adjusting serotonin levels in the brain. Some of these drugs include fluoxetine, sertraline and paroxetine since they have been found effective in various health care facilities.
• Topical agents such as Lidocaine and benzocaine use topical action to reduce the sensitivity to the penis to help the man have a longer businessman. These treatments are preferred mostly due to the ability of fast onset of action coupled with ease of administration. There are other classes of drugs which enhance sexual performance through facilitating blood flow to the penis that include sildenafil and tadalafil which also play helpful role in PE. However, there are other types of drugs, such as herbal drugs and others that are still undergoing tests on the reliable benefits they can offer in handling premature ejaculation. Such options are being considered, but they are not nearly as popular as SSRIs and topical anesthetics.

Premature Ejaculation Treatment Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• For the same, it is predicted that in 2023, North American market will lead the premature ejaculation treatment market due to increasing awareness regarding sexual health problems, sophisticated healthcare facilities, and various treatments available. Among the countries, dominating the market are the United States where there are moreover notable enumerated pharmaceutical manufacturing firms and where concerns flanking medical impact linked sexual health avails are numerous.
• North America has been projected to capture the 35-40% market of the global market in the year 2023. This region is in the dominant due to the following factors; including an ageing population, a rise in health care expenditure, and, a rising number of men seeking professional assistance on PEP.

Active Key Players in the Premature Ejaculation Treatment Market

• Alnylam Pharmaceuticals (United States)
• Anson Medical (United States)
• AstraZeneca (United Kingdom)
• Bayer AG (Germany)
• Biocon (India)
• Eresearchtechnology (United States)
• Ferring Pharmaceuticals (Switzerland)
• GSK (United Kingdom)
• Intas Pharmaceuticals (India)
• Johnson & Johnson (United States)
• Mylan N.V. (United States)
• Pfizer (United States)
• Sanofi (France)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Vicus Therapeutics (United States) and Other Active Players

Key Industry Developments of Premature Ejaculation Treatment Market

• In November 2023, Kanna Health announced that it received approvals from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin its Phase 1 clinical trial for KH-001 Besylate (KH-001). The FDA approved the company’s Investigational New Drug (IND) application, while the MHRA granted clearance for its Clinical Trial Application (CTA). These approvals allowed Kanna Health to initiate participant enrollment in a first-in-human trial evaluating the safety and pharmacokinetics of KH-001 in healthy male subjects.